Difficulty: Medium
Average Score: 89%
Practice
A 68-year-old man with recurrence of prostate cancer after prostatectomy has been receiving chemotherapy treatments. His last prostate-specific antigen (PSA) was 1.4. The chemotherapy has caused a decrease in production from his bone marrow. His hemoglobin is 9.6 g/dL, hematocrit is 28.1%, and platelet count is 44,000/μL. What medication can be given to stimulate bone marrow production of platelets?
Correct answer
D
Rationale
In this scenario, the correct medication to stimulate bone marrow production of platelets for the 68-year-old man with prostate cancer undergoing chemotherapy is option D) Oprelvekin. Oprelvekin is a thrombopoietic growth factor that stimulates the production of platelets from the bone marrow.
Option A) Aldesleukin is a cytokine used to treat certain types of cancer but does not specifically target platelet production. Option B) Erythropoietin stimulates red blood cell production, not platelets. Option C) Filgrastim is a granulocyte colony-stimulating factor that primarily stimulates white blood cell production and is not indicated for platelet production.
Educationally, it is important to understand the specific mechanisms of action of different medications to appropriately treat patients. In this case, knowing that Oprelvekin is a thrombopoietic growth factor helps in selecting the right medication to address the low platelet count caused by chemotherapy-induced bone marrow suppression. Understanding these concepts is crucial for healthcare providers to make informed decisions in patient care.
Option A) Aldesleukin is a cytokine used to treat certain types of cancer but does not specifically target platelet production. Option B) Erythropoietin stimulates red blood cell production, not platelets. Option C) Filgrastim is a granulocyte colony-stimulating factor that primarily stimulates white blood cell production and is not indicated for platelet production.
Educationally, it is important to understand the specific mechanisms of action of different medications to appropriately treat patients. In this case, knowing that Oprelvekin is a thrombopoietic growth factor helps in selecting the right medication to address the low platelet count caused by chemotherapy-induced bone marrow suppression. Understanding these concepts is crucial for healthcare providers to make informed decisions in patient care.